Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of March 2021, with a report date of March 16, 2021. The registrant is a foreign private issuer based in Jerusalem, Israel, filing under Rule 13a-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
- Executive Leadership: Mr. Amir Reichman assumed the position of Chief Executive Officer on a full-time basis on March 2, 2021.
- Board Composition: Mr. Ron Babecoff resigned from the Board of Directors effective March 8, 2021.
- Advisory Role: Mr. Babecoff will continue to serve as a Senior Advisor to the Company following his resignation.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the aforementioned personnel changes and incorporates the report by reference into the Company's Registration Statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the effective dates of Mr. Reichman's full-time CEO appointment and Mr. Babecoff's board resignation.
- Confirm the continued role of Mr. Babecoff as a Senior Advisor.
- Review the referenced Registration Statements (Form F-3 No. 333-240189 and Form S-8 No. 333-239344) for broader context on capital raising or equity plans.